Cytokinetics' Myqorzo shows positive ACACIA-HCM trial data for nHCM at ESC, potentially doubling market reach; priced at $108,400 per year, competing with BMS' Camzyos.
MUNICH — Cytokinetics’ heart drug Myqorzo could gain expanded approval next year, potentially doubling its market reach, after detailed results backed the drug’s use in a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ESC: Cytokinetics delves deeper on ‘huge’ Myqorzo readout, fueling cardiomyopathy expansion bid
Cytokinetics details trial win for what could be its next approval
Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position
Aficamten improves health status, exercise capacity in challenging nonobstructive HCM
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Nonobstructive Heart Enlargement Responds to Aficamten
FDA extends review of Capricor cell therapy; Pain drug startup to go public
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
For decades, drugmakers have been confounded in the clinic by a rare form of hypertrophic cardiomyopathy. | Cytokinetics' cardiac…
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and…
Cytokinetics executives said their first FDA-approved drug is off to a strong start as it goes up against its Bristol Myers…
It took Cytokinetics 27 years to win its first drug approval. With the results of a new trial, its second could come much faster.
Cytokinetics sued Bristol Myers Squibb to invalidate a patent on Camzyos, claiming it unfairly targets its rival heart drug…
